Safety and efficacy of NOAC vs. VKA in patients treated by PCI: a retrospective study of the FRANCE PCI registry

IntroductionDual antithrombotic therapy (DAT) combining oral anticoagulation (OAC), preferentially Non-vitamin K antagonist OAC (NOAC) and single antiplatelet therapy (SAPT) for a period of 6–12 months is recommended after percutaneous coronary intervention (PCI) in patients with an indication for O...

Full description

Bibliographic Details

Published in:	Frontiers in Cardiovascular Medicine
Main Authors:	Eric Durand, Thibault Verrez, Andre Gillibert, Thomas Levesque, Thomas Barbe, René Koning, Pascal Motreff, Hélène Eltchaninoff, Jean-Philippe Collet, Gregoire Rangé
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Subjects:	PCI VKA NOAC bleeding atrial fibrillation
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2023.1320001/full